Search results for "Juva"

showing 10 items of 739 documents

Preoperative chemoradiation may not always be needed for patients with T3 and T2N+ rectal cancer

2011

BACKGROUND: Preoperative chemoradiation is becoming the standard treatment for patients with locally advanced rectal cancer. However, since the introduction of total mesorectal excision (TME), local recurrence rates have been reduced significantly, and some patients can be spared from potentially toxic over treatment. The current study was designed to assess the factors that predict recurrence in an institutional series of patients with rectal cancer who had clinical T2 lymph node-positive (cT2N+) tumors or cT3N0/N+ tumors and underwent radical surgery without receiving preoperative chemoradiation. METHODS: Between November 1997 and November 2008, the authors' multidisciplinary group preope…

AdultMaleCancer Researchmedicine.medical_specialtyColorectal cancermedicine.medical_treatmentAdenocarcinomaDisease-Free SurvivalmedicineHumansRadical surgerySurvival rateAgedNeoplasm StagingMesorectalAged 80 and overRectal Neoplasmsbusiness.industryStandard treatmentCancerMiddle Agedmedicine.diseaseCombined Modality TherapyTotal mesorectal excisionNeoadjuvant TherapySurgerySurvival RateRadiation therapyTreatment OutcomeOncologyLymphatic MetastasisFemaleNeoplasm Recurrence LocalbusinessCancer
researchProduct

Comparison of Different Nodal Staging in Patients With Locally Advanced Mid-low Rectal Cancer After Long-term Neoadjuvant Chemoradiation Therapy.

2019

Background/Aim: The aim of this study was to compare the ability of different lymph nodal staging systems to predict cancer recurrence in a multicenter European series of patients who underwent proctectomy after neoadjuvant chemoradiotherapy for locally advanced rectal cancer. Patients and Methods: Data on 170 consecutive patients undergoing proctectomy after neoadjuvant therapy for cT3-4 or cN+ rectal adenocarcinoma were retrieved from the European MRI and Rectal Cancer Surgery database. The prognostic role of the number of retrieved and examined nodes, nodal ratio, and log odds of positive lymph nodes (LODDS) was analyzed and compared by receiver operating characteristic curves, Pearson t…

AdultMaleCancer Researchmedicine.medical_specialtyMultivariate analysisColorectal cancerDisease-free survivalmedicine.medical_treatmentLODDSLocally advancedAdenocarcinomaDisease-Free SurvivalLog odds of positive lymph nodeRectal AdenocarcinomaMedicineHumansRectal cancerLog odds of positive lymph nodesNeoadjuvant therapyAgedNeoplasm StagingAged 80 and overReceiver operating characteristicddc:617business.industryRectal NeoplasmsHazard ratioGeneral MedicineNodal ratioChemoradiotherapyMiddle Agedmedicine.diseasePrognosisConfidence intervalNeoadjuvant TherapyOncologydisease-free survival; lodds; log odds of positive lymph nodes; neoadjuvant therapy; nodal ratio; rectal cancer; adenocarcinoma; adult; aged; aged 80 and over; disease-free survival; female; humans; lymph nodes; male; middle aged; neoplasm recurrence Local; Neoplasm Staging; Prognosis; Rectal Neoplasms; Chemoradiotherapy; Neoadjuvant TherapyNeoadjuvant therapyFemaleRadiologyLymph NodesNeoplasm Recurrence LocalbusinessAnticancer research
researchProduct

Rectal cancer: mucinous carcinoma on magnetic resonance imaging indicates poor response to neoadjuvant chemoradiation.

2010

Purpose To assess response of locally advanced rectal carcinoma to chemoradiation with regard to mucinous status and local tumor invasion found at pretherapeutic magnetic resonance imaging (MRI). Methods and Materials A total of 88 patients were included in this prospective study of patients with advanced mrT3 and mrT4 carcinomas. Carcinomas were categorized by MRI as mucinous (mucin proportion >50% within the tumor volume), and as nonmucinous. Patients received neoadjuvant chemoradiation consisting of 50.4 Gy (1.8 Gy/fraction) and 5-fluorouracil on Days 1 to 5 and Days 29 to 33. Therapy response was assessed by comparing pretherapeutic MRI with histopathology of surgical specimens (minimum…

AdultMaleCancer Researchmedicine.medical_specialtyPathologyAntimetabolites AntineoplasticNeoplasm ResidualColorectal cancerRectumDrug Administration SchedulemedicineMucinous carcinomaHumansRadiology Nuclear Medicine and imagingNeoplasm InvasivenessProspective StudiesProspective cohort studyAgedNeoplasm StagingAged 80 and overRadiationmedicine.diagnostic_testbusiness.industryRectal NeoplasmsCarcinomaDose fractionationMagnetic resonance imagingChemoradiotherapyMiddle Agedmedicine.diseaseAdenocarcinoma MucinousMagnetic Resonance ImagingNeoadjuvant TherapyTumor Burdenmedicine.anatomical_structureTreatment OutcomeOncologyAdenocarcinomaHistopathologyFemaleRadiologyDose Fractionation RadiationFluorouracilbusinessInternational journal of radiation oncology, biology, physics
researchProduct

Correlation between GP-170 expression, prognosis, and chemoresistance of superficial bladder carcinoma.

2003

To study GP-170 in superficial bladder cancer at initial diagnosis and at recurrence and to evaluate if intravesical chemoprophylaxis modifies the expression of GP-170 in tumor recurrences. GP-170 was retrospectively assessed in 160 patients affected by primary superficial transitional cell carcinoma of the bladder and followed for up to 10 years. Eighty-four patients (52.5%) recurred after transurethral resection (TUR). Adjuvant intravesical chemotherapy after TUR was adopted in 52 patients. The correlations between GP-170 and G-grade, T-category, risk of recurrence and of progression, and adoption of adjuvant intravesical chemotherapy were investigated. The correlations between variations…

AdultMaleCancer Researchmedicine.medical_specialtyPathologymedicine.medical_treatmentUrologySettore MED/24 - UrologiaSuperficial bladder carcinoma GP-170 MDR-1 Prognosis Intravesical chemotherapyInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineCarcinomaHumansATP Binding Cassette Transporter Subfamily B Member 1Stage (cooking)AgedRetrospective StudiesChemotherapyHematologyUrinary bladderbusiness.industryGeneral MedicineMiddle Agedmedicine.diseasePrognosisDrug Resistance MultipleGene Expression Regulation NeoplasticTransitional cell carcinomamedicine.anatomical_structureOncologyUrinary Bladder NeoplasmsChemotherapy AdjuvantDrug Resistance NeoplasmChemoprophylaxisFemaleSuperficial Bladder CarcinomaGenes MDRNeoplasm Recurrence LocalbusinessFollow-Up StudiesJournal of cancer research and clinical oncology
researchProduct

Modulation of 5-fluorouracil as adjuvant systemic chemotherapy in colorectal cancer: the IGCS-COL multicentre, randomised, phase III study

2005

The aims of this multicentre, randomised phase III trial were to evaluate: (1) the role of levamisol (LEV); and (2) the role of folinic acid (FA), added to 5-fluorouracil (5FU) in the adjuvant treatment of colorectal cancer. Patients with histologically proven, radically resected stage II or III colon or rectal cancer were eligible. The study had a 2x2 factorial design with four treatment arms: (a) 5FU alone, (b) 5FU+LEV, (c) 5FU+FA, (d) 5FU+LEV+FA, and two planned comparisons, testing the role of LEV and of FA, respectively. From March 1991, to September 1998, 1327 patients were randomised. None of the two comparisons resulted in a significant disease-free (DFS) or overall (OAS) survival a…

AdultMaleCancer Researchmedicine.medical_specialtyRandomization5-fluorouracil modulation; adjuvant chemotherapy; colorectal cancermedicine.drug_classColorectal cancerLeucovorincolorectal cancerAntimetaboliteGastroenterologyDisease-Free SurvivalFolinic acidRECTAL CANCER5-fluorouracil modulationCOLONInternal medicineClinical StudiesAntineoplastic Combined Chemotherapy ProtocolsmedicineMucositisHumansAgedbusiness.industryHazard ratioMiddle Agedmedicine.diseaseSurgeryadjuvant chemotherapyTreatment OutcomeLevamisoleOncologyChemotherapy AdjuvantFluorouracilVomitingFemaleFluorouracilmedicine.symptomColorectal Neoplasmsbusinessmedicine.drugBritish Journal of Cancer
researchProduct

Radiation response non-invasively imaged by [18F]FDG-PET predicts local tumor control and survival in advanced oral squamous cell carcinoma

2003

It is a major challenge to preoperatively identify patients who will profit from surgery of advanced oral cancer. In multimodality therapy, response to neoadjuvant radiation correlates to treatment success. Hence, for preoperative decisions, assessment of treatment response is required. Therefore, we analysed the prognostic significance of glucose metabolism after preoperative radiotherapy. [(18)F]FDG-PET investigations were performed for re-staging 35 patients after neoadjuvant radiotherapy (36Gy) immediately prior to tumor resection. Emission and transmission measurements were obtained and SUV's were calculated for the sites of maximum [(18)F]FDG-uptake. Subpopulations of "low" (SUV4) and…

AdultMaleCancer Researchmedicine.medical_treatmentStandardized uptake valuePremisesFluorodeoxyglucose F18Odds RatiomedicineHumansRadical surgerySurvival rateSurvival analysisNeoadjuvant therapyAgedAged 80 and overAnalysis of Variancebusiness.industryMiddle AgedPrognosisNeoadjuvant TherapySurvival RateRadiation therapyTreatment OutcomeOncologyEpidermoid carcinomaMultivariate AnalysisCarcinoma Squamous CellFemaleMouth NeoplasmsRadiotherapy AdjuvantRadiopharmaceuticalsOral SurgeryNuclear medicinebusinessFollow-Up StudiesTomography Emission-ComputedOral Oncology
researchProduct

Correction to: Adjunctive Brivaracetam in Focal Epilepsy: Real‑World Evidence from the BRIVAracetam add‑on First Italian netwoRk Study (BRIVAFIRST)

2021

In randomized controlled trials, add-on brivaracetam (BRV) reduced seizure frequency in patients with drug-resistant focal epilepsy. Studies performed in a naturalistic setting are a useful complement to characterize the drug profile.This multicentre study assessed the effectiveness and tolerability of adjunctive BRV in a large population of patients with focal epilepsy in the context of real-world clinical practice.The BRIVAFIRST (BRIVAracetam add-on First Italian netwoRk STudy) was a retrospective, multicentre study including adult patients prescribed adjunctive BRV. Patients with focal epilepsy and 12-month follow-up were considered. Main outcomes included the rates of seizure-freedom, s…

AdultMaleDrug Resistant EpilepsyLevetiracetamEpilepsy CNS therapyCorrectionMiddle AgedSettore MED/26PyrrolidinonesPsychiatry and Mental healthTreatment OutcomeItalyChemotherapy AdjuvantHumansPharmacology (medical)AnticonvulsantsFemaleNeurology (clinical)Epilepsies PartialRetrospective Studies
researchProduct

Spinal ependymoma in adults: a multicenter investigation of surgical outcome and progression-free survival

2018

OBJECTIVESpinal ependymomas are rare glial neoplasms. Because their incidence is low, only a few larger studies have investigated this condition. There are no clear data concerning prognosis and therapy. The aim of the study was to describe the natural history, perioperative clinical course, and local tumor control of adult patients with spinal ependymomas who were surgically treated under modern treatment standards.METHODSThe authors performed a multicenter retrospective study. They identified 158 adult patients with spinal ependymomas who had received surgical treatment between January 2006 and June 2013. The authors analyzed the clinical and histological aspects of these cases to identif…

AdultMaleEpendymomaMicrosurgerymedicine.medical_specialtyAdolescentSpinal intradural tumormedicine.medical_treatmentYoung Adult03 medical and health sciences0302 clinical medicineRecurrenceNeoplasmsBiomarkers TumormedicineHumansSpinal Cord NeoplasmsProgression-free survivalGrading (tumors)AgedRetrospective StudiesAged 80 and overSpinal cordbusiness.industryIncidence (epidemiology)Retrospective cohort studyGeneral MedicinePerioperativeMiddle AgedPrognosismedicine.diseaseProgression-Free Survivalddc:616.8SurgeryRadiation therapyKi-67 AntigenLocalOncologyEpendymomaTumor progression030220 oncology & carcinogenesisFemaleRadiotherapy AdjuvantNeoplasm Recurrence Localbusiness030217 neurology & neurosurgeryFollow-Up StudiesJournal of Neurosurgery: Spine
researchProduct

Classification of orbital exenteration and reconstruction

2017

Orbital exenteration (OE) is considered to be a mutilating surgical procedure reserved for relentlessly progressive neoplastic disorders or extensive facial trauma with unfavourable eye involvement. Malignant tumours, accounting for the majority of ablative orbital surgeries, may be caused by primary orbital tumours or secondarily by neoplasias from the surrounding skin, the maxillary sinus or intracranial malignomas. Orbital exenteration following trauma is mostly caused by penetrating globe defects or extended infections with the danger of intracranial effects. Thoughtful resection planning, the exploitation of reconstructive possibilities as well as the consideration of adjuvant therapy …

AdultMaleFacial traumaReconstructive surgerymedicine.medical_specialtyAdolescentgenetic structuresMaxillary sinusmedicine.medical_treatmentOphthalmologic Surgical ProceduresFree flapYoung Adult03 medical and health sciences0302 clinical medicineAblative caseAdjuvant therapyHumansMedicineChildOrbit EviscerationAgedRetrospective StudiesAged 80 and overbusiness.industryGuidelineMiddle AgedPlastic Surgery ProceduresMicrosurgerymedicine.diseaseeye diseasesSurgerymedicine.anatomical_structureOtorhinolaryngology030220 oncology & carcinogenesis030221 ophthalmology & optometryFemaleSurgeryOral SurgerybusinessAlgorithmsJournal of Cranio-Maxillofacial Surgery
researchProduct

[Conservative treatment of locally advanced bladder carcinoma: neoadjuvant chemotherapy, TUR and radiotherapy. Results in 40 patients]

1998

to assess the results of bladder preservation in infiltrating bladder cancer. The potential for neoadjuvant chemotherapy followed by extensive TUR and radiotherapy was investigated in 40 patients with T2-T4a G2-G3 bladder carcinoma.from 1983 to 1995, 40 patients were submitted to bladder-sparing treatment consisting of neoadjuvant chemotherapy, extensive, TUR and radiotherapy. Most patients had T3G3 cancer. Cystectomy was not performed due to patient" choice in 29 cases (72.5%), for severe pulmonary or cardiovascular disease in disease in 9 patients (22.5) and age over 80 in 2 (5%) patients. A deep TUR-biopsy was performed before and after chemotherapy and an extensive TUR was repeated at t…

AdultMaleNeoplasm ResidualBiopsyCystectomyVinblastineAntineoplastic Combined Chemotherapy ProtocolsPreoperative CareHumansNeoplasm InvasivenessNeoplasm MetastasisAgedAged 80 and overNeoplasm InvasiveneAntineoplastic Combined Chemotherapy ProtocolRemission InductionMiddle AgedNeoplasm MetastasiMethotrexateUrinary Bladder NeoplasmsChemotherapy AdjuvantEvaluation Studies as TopicUrinary Bladder NeoplasmFemaleRadiotherapy AdjuvantCisplatinNeoplasm Recurrence LocalHuman
researchProduct